Sarcoidosis is a multisystem disease characterized by noncaseating epithelioid cell granuloma. Although the etiology and pathogenesis of sarcoidosis is unknown, it is believed to be related to genetic susceptibility, environmental factors, and abnormal immune response. In general, the diagnosis of sarcoidosis is based on compatible clinical and radiologic features, histological evidence of noncaseating epithelioid cell granulomas, and exclusion of other granulomas disease. With the development of new technology, biomarkers, CT pattern scores and PET-CT have been applied to the improvement of diagnosis and organ involvement assessment.
Some patients with pulmonary sarcoidosis do not require systemic treatment based on a certain spontaneous remission rate. Therefore, the treatment of sarcoidosis needs to formulate an effective individualized plan according to the clinical manifestations, involving organ and their severity and basic diseases. The most common indication for pulmonary disease treatment is the development of respiratory symptoms, followed with extra-pulmonary involvement of cardiovascular, and neurologic systems.
At present, drugs for sarcoidosis include corticosteroids as first-line therapy, and cytotoxic drugs as second-line treatment and anti-tumor necrosis factor (TNF) biologics as third-line agents. In addition, some novel therapeutic agents such as Acthar Gel and rituximab have been studied for sarcoidosis and get some positive results.
In this research topic, we aim to provide a recent progress in diagnosis and treatment of sarcoidosis and seek innovative solutions to resolve existing challenges.
We welcome Original Research, Review, and Mini-review covering, but not limited to the following subjects:
• Clinical trial of new drugs for sarcoidosis
• Sarcoidosis cohort study
• New techniques for diagnosis and differential diagnosis of sarcoidosis
• Establishment and application of sarcoidosis diagnostic model
• The role of sarcoidosis biomarkers in diagnosis and prognosis
• New targets for sarcoidosis treatment
Sarcoidosis is a multisystem disease characterized by noncaseating epithelioid cell granuloma. Although the etiology and pathogenesis of sarcoidosis is unknown, it is believed to be related to genetic susceptibility, environmental factors, and abnormal immune response. In general, the diagnosis of sarcoidosis is based on compatible clinical and radiologic features, histological evidence of noncaseating epithelioid cell granulomas, and exclusion of other granulomas disease. With the development of new technology, biomarkers, CT pattern scores and PET-CT have been applied to the improvement of diagnosis and organ involvement assessment.
Some patients with pulmonary sarcoidosis do not require systemic treatment based on a certain spontaneous remission rate. Therefore, the treatment of sarcoidosis needs to formulate an effective individualized plan according to the clinical manifestations, involving organ and their severity and basic diseases. The most common indication for pulmonary disease treatment is the development of respiratory symptoms, followed with extra-pulmonary involvement of cardiovascular, and neurologic systems.
At present, drugs for sarcoidosis include corticosteroids as first-line therapy, and cytotoxic drugs as second-line treatment and anti-tumor necrosis factor (TNF) biologics as third-line agents. In addition, some novel therapeutic agents such as Acthar Gel and rituximab have been studied for sarcoidosis and get some positive results.
In this research topic, we aim to provide a recent progress in diagnosis and treatment of sarcoidosis and seek innovative solutions to resolve existing challenges.
We welcome Original Research, Review, and Mini-review covering, but not limited to the following subjects:
• Clinical trial of new drugs for sarcoidosis
• Sarcoidosis cohort study
• New techniques for diagnosis and differential diagnosis of sarcoidosis
• Establishment and application of sarcoidosis diagnostic model
• The role of sarcoidosis biomarkers in diagnosis and prognosis
• New targets for sarcoidosis treatment
